California Public Employees Retirement System Sells 2,962 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

California Public Employees Retirement System decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 96,011 shares of the medical research company’s stock after selling 2,962 shares during the quarter. California Public Employees Retirement System’s holdings in Charles River Laboratories International were worth $22,697,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock worth $1,166,837,000 after buying an additional 29,482 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Charles River Laboratories International by 3.9% during the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,746,101 shares of the medical research company’s stock worth $342,201,000 after buying an additional 64,981 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,195,226 shares of the medical research company’s stock worth $234,241,000 after buying an additional 6,398 shares in the last quarter. Ariel Investments LLC lifted its position in shares of Charles River Laboratories International by 1.8% during the 3rd quarter. Ariel Investments LLC now owns 1,066,600 shares of the medical research company’s stock worth $209,032,000 after buying an additional 18,760 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Charles River Laboratories International by 8.9% during the 3rd quarter. Invesco Ltd. now owns 927,895 shares of the medical research company’s stock worth $181,849,000 after buying an additional 75,978 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity

In other news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now directly owns 13,550 shares in the company, valued at approximately $3,437,635. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 in the last three months. Corporate insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on CRL. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. UBS Group lifted their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Argus lifted their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Charles River Laboratories International Stock Up 0.5 %

Charles River Laboratories International stock opened at $229.03 on Monday. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The firm has a market capitalization of $11.80 billion, a price-to-earnings ratio of 24.87, a P/E/G ratio of 1.79 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The firm has a 50 day simple moving average of $253.48 and a 200 day simple moving average of $223.01.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.98 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).